Tazverik (tazemetostat)
Various cancers
CommercialDiscontinuation announced
Key Facts
About Eisai
Eisai is a Japanese pharmaceutical giant with a strong commitment to human health care (hhc), focusing on addressing unmet medical needs in neurology, oncology, and neglected tropical diseases. The company has achieved significant breakthroughs in Alzheimer's treatment with Lecanemab and maintains a robust oncology portfolio including multi-targeted kinase inhibitors. Eisai is also deeply committed to global health initiatives, providing treatments for neglected tropical diseases in developing countries while maintaining strong financial performance as a publicly traded company.
View full company profileOther Various cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Retifanlimab | Eli Lilly | Phase 2/3 |
| Imfinzi (durvalumab) | AstraZeneca | Approved |
| Lynparza (olaparib) | Merck | Commercial |
| Oncology Portfolio | Pfizer | Phase 1-3 |
| PD-1 Inhibitor | Akeso | Phase 2/3 |
| Mitoxantrone Liposome | CSPC Pharmaceutical Group Limited | Phase 3 |
| Biosimilar Bevacizumab | Cipla | Commercial |
| Oncology Generics | Aurobindo Pharma | Commercial |
| Opdivo (nivolumab) | Ono Pharmaceutical | Approved |
| Oncology APIs (e.g., Sorafenib, Lenalidomide) | Laurus Labs | Commercial/Filed |
| Tumor Marker Portfolio (PSA, CA125, etc.) | H.U. Group Holdings | Commercial |
| Logic-gated Switch-DARPins | Molecular Partners | Preclinical |